{"id":4668,"date":"2024-10-08T12:20:39","date_gmt":"2024-10-08T02:20:39","guid":{"rendered":"\/eu-uk\/?p=4668"},"modified":"2024-10-08T12:20:39","modified_gmt":"2024-10-08T02:20:39","slug":"orthocell-receives-regulatory-approval-for-remplir-in-singapore","status":"publish","type":"post","link":"\/eu-uk\/blog\/2024\/10\/08\/orthocell-receives-regulatory-approval-for-remplir-in-singapore\/","title":{"rendered":"Orthocell Receives Regulatory Approval for Remplir\u2122 in Singapore\u00a0"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of its market leading nerve repair product, Remplir\u2122<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This marks the first major international approval of Remplir outside of Australia and New Zealand.\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Singapore is a strategic regulatory jurisdiction, both as a destination for sophisticated medical treatments in the region and as a regulatory gateway to other substantial ASEAN markets. Orthocell is also in advanced discussions with an experienced international medical device distributor ahead of the Singapore market launch anticipated for Q1 CY25.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Orthocell CEO and MD, Paul Anderson, said:\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cWe are delighted to receive Singaporean regulatory approval for Remplir in this important regional gateway market. This approval is further validation of Orthocell\u2019s, high-quality product, manufacturing processes and expanding global footprint. This approval strengthens our position to increase revenue and builds further confidence in our US FDA clearance anticipated in Q1 2025.\u201d<\/span><\/p>\n<p><a href=\"https:\/\/bit.ly\/OCC-Singapore-Approval\"><b>Click to read the ASX Release.<\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of its market leading nerve repair product, Remplir\u2122<\/p>\n","protected":false},"author":2,"featured_media":4671,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4668","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4668"}],"version-history":[{"count":1,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4668\/revisions"}],"predecessor-version":[{"id":4670,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4668\/revisions\/4670"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4671"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4668"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}